Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Wants A Breakthrough Therapy, Even Without All The Standards

Executive Summary

A few requests have gone to FDA for candidates to be named breakthrough therapies and gain access to shorter development programs, but the agency has not established all the program requirements yet.

You may also be interested in...



US FDA's Biologics Center Director Expects It Soon Will See 'Growth Spurt'

With cell and gene therapies becoming more popular, CBER Director Marks says in an interview with the Pink Sheet that more staff may be needed soon.

Breakthrough Designation Can Be 'Lever' For Manufacturing Evolution, FDA Says

CDER Director Woodcock notes breakthrough program often pushes sponsors to modernize production processes.

Primer On FDA’s "Breakthrough Therapy" Program

A look at the genesis of the US expedited regulatory pathway for drugs and biologics, its benefits, and how the program is working today.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS054838

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel